Multiple myeloma (MM) is a heterogeneous malignancy of abnormal plasma cells in the bone marrow. Recently, our team has identified CD46 as a novel therapeutical target for MM.

With selective targeting of CD46, we are able to provide precise therapy of MM while keeping healthy tissues intact. Our strategy focuses on utilizing YS5 antibody as a platform for CD46-directed theranostics, loading the target with either ²²⁵Ac or ⁸⁹Zr. We have developed and evaluated radioimmunoconjugate [²²⁵Ac]DOTA-YS5 for radioligand therapy and immunoPET agent [⁸⁹Zr]DFO-YS5 of MM. [⁸⁹Zr]DFO-YS5 has been IRB-approved for the imaging of MM in patients and a clinical trial has been opened (NCT05892393).

Figure: We have reported the preclinical evaluation of the immunoPET agent [⁸⁹Zr]DFO-YS5, demonstrating with high tumor uptake. Radioligand therapy with radioimmunoconjugate [²²⁵Ac]DOTA-YS5, showed promising antitumor efficacy reducing tumor burden and improving overall survival in a disseminated model of MM.

We are actively recruiting patients. For more information on the clinical trial, please visit ClinicalTrials.gov.

For more information, refer to our published work:

Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Clin Cancer Res. 2024 Mar 1;30(5):1009-1021. doi: 10.1158/1078-0432.CCR-23-2130. PMID: 38109209; PMCID: PMC10905524.